Company news
Pharmacyte Biotech, Inc. (NASDAQ:PMCB) news
Pharmacyte Biotech, Inc. news releases on 6ix. Latest, Aug 25, 2021: PharmaCyte Biotech Expands Product Pipeline to Include Diabetes and Malignant Ascites…
Press releases — page 2
PharmaCyte Biotech Expands Product Pipeline to Include Diabetes and Malignant Ascites Following $90-Million Capital Raise
August 24, 2021
PharmaCyte Biotech Announces Closing of $70 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
August 22, 2021
PharmaCyte Biotech Announces $70 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
August 18, 2021
PharmaCyte Biotech Releases Statement on Nasdaq Uplisting and Current Business Focus
August 15, 2021
PharmaCyte Biotech Announces Closing of $15-Million Public Offering
August 11, 2021
PharmaCyte Biotech Announces Uplist Date to NASDAQ and Pricing of $15 Million Public Offering
August 8, 2021
PharmaCyte Biotech Announces Uplist to The Nasdaq Capital Market and Launch of Public Offering
August 1, 2021
PharmaCyte Biotech Provides Update to Nasdaq Listing Efforts and Presents Scientific Publications Supporting Pancreatic Cancer Treatment
July 21, 2021
PharmaCyte Biotech Announces Update on Study Progress and Uplist to Nasdaq
July 13, 2021
PharmaCyte Biotech Announces Stability Test Results on Cells from Master Cell Bank
July 11, 2021
PharmaCyte Biotech Announces Reverse Stock Split
July 8, 2021
PharmaCyte Biotech Announces Results of Vote at Annual Meeting of Stockholders
July 7, 2021
PharmaCyte Biotech Provides Update on Status of Activities to Lift Clinical Hold
June 23, 2021
PharmaCyte Biotech Announces Shareholders Vote to Increase the Authorized Capital
June 21, 2021
PharmaCyte Biotech Announces Adjournment of Annual Meeting of Stockholders, Recording of Stockholder Meeting Available
June 17, 2021
PharmaCyte Biotech Announces Details to Attend This Week’s Virtual Annual Meeting of Shareholders
June 13, 2021
PharmaCyte Biotech Successfully Completes 1 Year Stability Study
March 31, 2021
PharmaCyte Biotech Begins DNA Sequence and Stability Studies in Response to FDA Requests for its Clinical Trial Product
January 25, 2021
PharmaCyte Biotech Begins Physical Testing of CypCaps in Response to FDA Recommendations for its Clinical Trial Product
December 13, 2020
PharmaCyte Biotech Successfully Completes 9-Month Stability Study
December 1, 2020
PharmaCyte Biotech Receives U.S. FDA Clinical Hold Letter
November 3, 2020
PharmaCyte Biotech’s Investigational New Drug Application Placed on Hold by the U.S. FDA
October 1, 2020
PharmaCyte Biotech Continues to Engage the FDA During 30-Day Comment Period
September 22, 2020
PharmaCyte Biotech Successfully Completes Six-Month Stability Study
September 13, 2020
PharmaCyte Biotech Successfully Completes Second Container Closure Integrity Test
September 7, 2020
PharmaCyte Biotech Announces IND Submitted to U.S. FDA for Clinical Trial in Locally Advanced, Inoperable Pancreatic Cancer
September 1, 2020
PharmaCyte Biotech Appoints Dr. José Iglesias as Consulting Chief Medical Officer for Clinical Trial in Pancreatic Cancer
August 9, 2020
FDA Formally Accepts PharmaCyte Biotech’s Drug Master File for Company’s Pancreatic Cancer Therapy
August 4, 2020
PharmaCyte Biotech Ready to Submit Investigational New Drug Application to FDA for Clinical Trial in Pancreatic Cancer
August 2, 2020
PharmaCyte Biotech Receives CE Mark for Licensed COVID-19 Molecular Tests
July 28, 2020
PharmaCyte Biotech Announces Submission of Drug Master File to FDA for Company’s Pancreatic Cancer Therapy
July 26, 2020
PharmaCyte Biotech Successfully Completes Container Closure Integrity Test
July 12, 2020
PharmaCyte Biotech Successfully Completes Three-Month Stability Study
July 7, 2020
PharmaCyte Biotech’s COVID-19 Test Offers “Pool Testing” Dr. Fauci and White House Coronavirus Task Force Now Considering
June 28, 2020
PharmaCyte Biotech Provides IND Submission Update for Pancreatic Cancer Clinical Trial
June 22, 2020
PharmaCyte Biotech Successfully Accelerates Development of Container Closure Integrity Test for Pancreatic Cancer Clinical Trial Product
June 14, 2020
PharmaCyte Biotech Successfully Develops “Change History” for its Clinical Trial Product for Pancreatic Cancer
June 9, 2020
PharmaCyte Biotech Completes Final cGMP Audit of Manufacturing Facility for Pancreatic Cancer Clinical Trial Product
June 7, 2020
PharmaCyte Biotech Announces Final Major Study for IND Submission Has Begun
May 25, 2020
PharmaCyte Biotech Conducting Final Audit of Manufacturing Facility after Batch Records Deemed cGMP Compliant
May 10, 2020
PharmaCyte Biotech Receives Medical Devices Registration and Submits Pre-EUA Application to the FDA for COVID-19 Diagnostic Kit
May 5, 2020
PharmaCyte Biotech Completes Medical Manual for IND Filing
May 3, 2020
PharmaCyte Biotech Successfully Completes Pyrogenicity Testing
April 26, 2020
PharmaCyte Biotech to Offer COVID-19 Testing While Creating Revenue Stream for Pancreatic Cancer Program
April 12, 2020
PharmaCyte Biotech Enters into License Agreement for COVID-19 Diagnostic Kits
April 7, 2020
PharmaCyte Biotech CEO Discusses Navigating Testing and IND Submission During COVID-19 Pandemic
March 25, 2020
PharmaCyte Biotech Addresses Submission of IND and Recent FDA-Required Testing
March 11, 2020
PharmaCyte Biotech Receives Certificates of Analysis and Batch Records for its Clinical Trial Product in Pancreatic Cancer
February 11, 2020
PharmaCyte Biotech Will Have All the Protection It Needs for Pancreatic Cancer Treatment Upon Marketing Approval
February 3, 2020
PharmaCyte Biotech’s Pancreatic Cancer Therapy Passes Critical FDA-Required Tests as Countdown to IND Submission Begins
January 26, 2020